213 related articles for article (PubMed ID: 34999723)
1. Complement cascade inhibition in geographic atrophy: a review.
Desai D; Dugel PU
Eye (Lond); 2022 Feb; 36(2):294-302. PubMed ID: 34999723
[TBL] [Abstract][Full Text] [Related]
2. Growth of geographic atrophy on fundus autofluorescence and polymorphisms of CFH, CFB, C3, FHR1-3, and ARMS2 in age-related macular degeneration.
Caire J; Recalde S; Velazquez-Villoria A; Garcia-Garcia L; Reiter N; Anter J; Fernandez-Robredo P; Alfredo García-Layana ;
JAMA Ophthalmol; 2014 May; 132(5):528-34. PubMed ID: 24557084
[TBL] [Abstract][Full Text] [Related]
3. Risk alleles in CFH and ARMS2 are independently associated with systemic complement activation in age-related macular degeneration.
Smailhodzic D; Klaver CC; Klevering BJ; Boon CJ; Groenewoud JM; Kirchhof B; Daha MR; den Hollander AI; Hoyng CB
Ophthalmology; 2012 Feb; 119(2):339-46. PubMed ID: 22133792
[TBL] [Abstract][Full Text] [Related]
4. Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes and phenotypes.
Reynolds R; Hartnett ME; Atkinson JP; Giclas PC; Rosner B; Seddon JM
Invest Ophthalmol Vis Sci; 2009 Dec; 50(12):5818-27. PubMed ID: 19661236
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Complement Cascade for Treatment of Dry Age-Related Macular Degeneration.
Patel PN; Patel PA; Land MR; Bakerkhatib-Taha I; Ahmed H; Sheth V
Biomedicines; 2022 Aug; 10(8):. PubMed ID: 36009430
[TBL] [Abstract][Full Text] [Related]
6. Targeting factor D of the alternative complement pathway reduces geographic atrophy progression secondary to age-related macular degeneration.
Yaspan BL; Williams DF; Holz FG; Regillo CD; Li Z; Dressen A; van Lookeren Campagne M; Le KN; Graham RR; Beres T; Bhangale TR; Honigberg LA; Smith A; Henry EC; Ho C; Strauss EC;
Sci Transl Med; 2017 Jun; 9(395):. PubMed ID: 28637922
[TBL] [Abstract][Full Text] [Related]
7. THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET.
Boyer DS; Schmidt-Erfurth U; van Lookeren Campagne M; Henry EC; Brittain C
Retina; 2017 May; 37(5):819-835. PubMed ID: 27902638
[TBL] [Abstract][Full Text] [Related]
8. Targeting complement components C3 and C5 for the retina: Key concepts and lingering questions.
Kim BJ; Mastellos DC; Li Y; Dunaief JL; Lambris JD
Prog Retin Eye Res; 2021 Jul; 83():100936. PubMed ID: 33321207
[TBL] [Abstract][Full Text] [Related]
9. Investigational drugs inhibiting complement for the treatment of geographic atrophy.
Ferro Desideri L; Artemiev D; Bernardi E; Paschon K; Zandi S; Zinkernagel M; Anguita R
Expert Opin Investig Drugs; 2023; 32(11):1009-1016. PubMed ID: 37902056
[TBL] [Abstract][Full Text] [Related]
10. Differential and Altered Spatial Distribution of Complement Expression in Age-Related Macular Degeneration.
Demirs JT; Yang J; Crowley MA; Twarog M; Delgado O; Qiu Y; Poor S; Rice DS; Dryja TP; Anderson K; Liao SM
Invest Ophthalmol Vis Sci; 2021 Jun; 62(7):26. PubMed ID: 34160562
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules.
Nebbioso M; Lambiase A; Cerini A; Limoli PG; La Cava M; Greco A
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30987401
[TBL] [Abstract][Full Text] [Related]
12. The complement system: a novel therapeutic target for age-related macular degeneration.
Shughoury A; Sevgi DD; Ciulla TA
Expert Opin Pharmacother; 2023; 24(17):1887-1899. PubMed ID: 37691588
[TBL] [Abstract][Full Text] [Related]
13. The ARMS2 A69S variant and bilateral advanced age-related macular degeneration.
Schwartz SG; Agarwal A; Kovach JL; Gallins PJ; Cade W; Postel EA; Wang G; Ayala-Haedo J; Spencer KM; Haines JL; Pericak-Vance MA; Scott WK
Retina; 2012 Sep; 32(8):1486-91. PubMed ID: 22481475
[TBL] [Abstract][Full Text] [Related]
14. Complement factor H in AMD: Bridging genetic associations and pathobiology.
Toomey CB; Johnson LV; Bowes Rickman C
Prog Retin Eye Res; 2018 Jan; 62():38-57. PubMed ID: 28928087
[TBL] [Abstract][Full Text] [Related]
15. Prevalence, Risk, and Genetic Association of Reticular Pseudodrusen in Age-related Macular Degeneration: Age-Related Eye Disease Study 2 Report 21.
Domalpally A; Agrón E; Pak JW; Keenan TD; Ferris FL; Clemons TE; Chew EY
Ophthalmology; 2019 Dec; 126(12):1659-1666. PubMed ID: 31558345
[TBL] [Abstract][Full Text] [Related]
16. [Association between Y402H, E318D and R102G polymorphisms of complement proteins genes and the response to intravitreal anti-VEGF treatment in patients with neovascular age-related macular degeneration].
Kubicka-Trząska A; Karska-Basta I; Kobylarz J; Dziedzina S; Sanak M; Romanowska-Dixon B
Klin Oczna; 2016; 118(2):114-21. PubMed ID: 29912491
[TBL] [Abstract][Full Text] [Related]
17. CFH, C3 and ARMS2 are significant risk loci for susceptibility but not for disease progression of geographic atrophy due to AMD.
Scholl HP; Fleckenstein M; Fritsche LG; Schmitz-Valckenberg S; Göbel A; Adrion C; Herold C; Keilhauer CN; Mackensen F; Mössner A; Pauleikhoff D; Weinberger AW; Mansmann U; Holz FG; Becker T; Weber BH
PLoS One; 2009 Oct; 4(10):e7418. PubMed ID: 19823576
[TBL] [Abstract][Full Text] [Related]
18. Incidence and progression of geographic atrophy: observations from a population-based cohort.
Joachim N; Mitchell P; Kifley A; Rochtchina E; Hong T; Wang JJ
Ophthalmology; 2013 Oct; 120(10):2042-50. PubMed ID: 23706948
[TBL] [Abstract][Full Text] [Related]
19. Systemic complement activation in age-related macular degeneration.
Scholl HP; Charbel Issa P; Walier M; Janzer S; Pollok-Kopp B; Börncke F; Fritsche LG; Chong NV; Fimmers R; Wienker T; Holz FG; Weber BH; Oppermann M
PLoS One; 2008 Jul; 3(7):e2593. PubMed ID: 18596911
[TBL] [Abstract][Full Text] [Related]
20. Emerging opportunities for C3 inhibition in the eye.
Kim BJ; Liu T; Mastellos DC; Lambris JD
Semin Immunol; 2022 Jan; 59():101633. PubMed ID: 35787973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
